Multilingual Theia Has Arrived!
The AdaptDx Pro and Theia will change the future of AMD care because they make it easier for eye care professionals to test more patients and diagnose disease at an earlier stage.
Subclinical AMD Detection
Research reveals that impaired dark adaptation is the earliest biomarker of AMD. Diagnosis at the subclinical level is the best chance to preserve vision.
Breakthrough Technology Meets High-Touch Patient Care
Measuring dark adaptation speed with the AdaptDx Pro® can be useful in diagnosing AMD at the subclinical stage and managing this progressive disease with the hope of preventing unnecessary vision loss.
The AdaptDx Pro is amazing for two primary reasons. One, the portability of it is phenomenal. The other piece that’s critical is that Theia, the onboard AI tech, provides the instructions for the test, so patients get consistent instructions every time.
Latest News & Upcoming EventsView More
How can we make timely referrals the norm, not the exception? Jessica Haynes, OD, shares how technology takes the guesswork out of monitoring and managing AMD suspects.
Dr. Lou shares how he needed to rethink AMD, and is proud to report that this allowed him to make a marked difference in disease management.
Read how AMD went undetected due to delayed care because a patient feared catching COVID at the doctor’s office.